Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 7.7277
- Book/Share 3.3466
- PB 4.062
- Debt/Equity 0.0
- CurrentRatio 0.8682
- ROIC 0.1098
- MktCap 57159835260.6907
- FreeCF/Share 0.8929
- PFCF 15.6903
- PE 18.2385
- Debt/Assets 0.0
- DivYield 0.0426
- ROE 0.2244
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
Read More
GSK may have numbers may have been flattered by order timing, says bank
Published: July 30, 2025 by: Proactive Investors
Sentiment: Neutral
GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous range. However, UBS analysts caution that much of this outperformance was driven by timing effects, such as early HIV medicine orders and stock builds, particularly in France for the Shingrix vaccine, which are likely to reverse later in the year.
Read More
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK (GSK) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.09 per share a year ago.
Read More
GSK in talks with Trump administration on U.S. drug pricing, CEO says
Published: July 30, 2025 by: Reuters
Sentiment: Neutral
British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressure from Washington to rein in prices.
Read More
GSK confident of hitting top end of 2025 targets after strong second quarter
Published: July 30, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the year after reporting a robust second quarter, fuelled by strong sales in its Specialty Medicines and Vaccines businesses. The pharmaceuticals giant posted sales of £8 billion for the three months to June, up 6% at constant exchange rates.
Read More
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
Published: July 28, 2025 by: Seeking Alpha
Sentiment: Positive
GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management's long-term revenue targets, I see limited near-term catalysts to drive significant EPS or share price appreciation. Financials reveal rising inventories and a stretched balance sheet compared to peers, making the current valuation potentially a value trap.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
GSK's blood cancer drug gets EU approval for multiple myeloma
Published: July 24, 2025 by: Reuters
Sentiment: Positive
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
Read More
US FDA extends review of GSK's blood cancer drug
Published: July 23, 2025 by: Reuters
Sentiment: Neutral
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
Read More
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need.
Read More
US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster). The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals. The existing vaccine presentation consists of two vials, a.
Read More
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
Read More
GSK seeks FDA nod for expanded use of RSV vaccine in adults
Published: July 14, 2025 by: Reuters
Sentiment: Positive
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age of 50 at a higher risk of the disease.
Read More
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
Published: July 10, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)--GSK begins shipping influenza vaccine doses for the 2025-26 flu season.
Read More
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
Read More
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
GSK counts on Blenrep rebound to drive £40bn sales goal
Published: July 03, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC's (LSE:GSK, NYSE:GSK) long-term growth ambitions hinge in part on Blenrep, its treatment for multiple myeloma, a type of blood cancer. With the company aiming for more than £40 billion in annual sales by 2031, investors are watching closely how this high-margin medicine performs in the clinic and in the market.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
US Senator investigates GSK for pulling children's asthma inhaler
Published: June 27, 2025 by: Reuters
Sentiment: Negative
Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.
Read More
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
Read More
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AstraZeneca and GSK fall after Trump renews pharma tariff threat
Published: June 18, 2025 by: Proactive Investors
Sentiment: Negative
Shares in AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 index, and fellow blue chip GSK PLC (LSE:GSK, NYSE:GSK) were down 1.4% and 1.9% respectively on renewed worries about US drug tariffs. The pharmaceutical pair were a large drag on the London index after US President Donald Trump said tariffs on imported drugs could be imposed “very soon”, echoing comments from two months ago.
Read More
Here's Why GSK (GSK) is a Strong Momentum Stock
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
Read More
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Published: June 16, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). “Too many people living with lupus face delays in diagnosis and disconnects in care,” said Court Horncastle, Senior Vice President at GSK. “With this initiative, we're proud to support the organizations working within local communities to improve.
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Published: June 09, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Emma Natasha Walmsley
- Employees 68629